{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:18:34Z","timestamp":1783574314757,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project","award":["(2024GYB24"],"award-info":[{"award-number":["(2024GYB24"]}]},{"name":"Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project","award":["(2024GYB24"],"award-info":[{"award-number":["(2024GYB24"]}]},{"name":"Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project","award":["(2024GYB24"],"award-info":[{"award-number":["(2024GYB24"]}]},{"name":"Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project","award":["(2024GYB24"],"award-info":[{"award-number":["(2024GYB24"]}]},{"name":"Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project","award":["(2024GYB24"],"award-info":[{"award-number":["(2024GYB24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05931-5","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:12:13Z","timestamp":1778893933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiafang","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"9","key":"5931_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","volume":"21","author":"NS Wilcox","year":"2024","unstructured":"Wilcox NS, Amit U, Reibel JB, et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21(9):617\u201331.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"5931_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-024-02078-0","volume":"23","author":"Z Li","year":"2024","unstructured":"Li Z, Gao Y, Lu Q, et al. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study. Lipids Health Dis. 2024;23(1):134.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"5931_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein J JP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1\/4. J Am Coll Cardiol. 2021;77(12):1564\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5931_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/clinchem\/hvad012","volume":"69","author":"NMA White-Al Habeeb","year":"2023","unstructured":"White-Al Habeeb NMA, Higgins V. The Present and Future of Lipid Testing in Cardiovascular Risk Assessment. Clin Chem. 2023;69(5):456\u201369.","journal-title":"Clin Chem"},{"issue":"12","key":"5931_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","volume":"120","author":"RS Wright","year":"2024","unstructured":"Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;120(12):1400\u201310.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"5931_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701\u201316.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"5931_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129\u201338.","journal-title":"Eur Heart J"},{"key":"5931_CR8","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480.","journal-title":"Pharmacol Ther"},{"issue":"15","key":"5931_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019donoghue","year":"2022","unstructured":"O\u2019donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319.","journal-title":"Circulation"},{"key":"5931_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/VHRM.S338424","volume":"19","author":"MS Albosta","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, et al. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023;19:421\u201331.","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"5931_CR11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1161\/STROKEAHA.123.045297","volume":"55","author":"MJ Dib","year":"2024","unstructured":"Dib MJ, Zagkos L, Meena D, et al. LDL-c lowering, ischemic stroke, and small vessel disease brain imaging biomarkers: a mendelian randomization study. Stroke. 2024;55(6):1676\u20139.","journal-title":"Stroke"},{"issue":"5","key":"5931_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11883-024-01199-2","volume":"26","author":"A Agarwala","year":"2024","unstructured":"Agarwala A, Asim R, Ballantyne CM. Oral PCSK9 inhibitors. Curr Atheroscler Rep. 2024;26(5):147\u201352.","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"5931_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5931_CR14","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.jlr.2024.100497","volume":"65","author":"MM Vroom","year":"2024","unstructured":"Vroom MM, Lu H, Lewis M, et al. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. J Lipid Res. 2024;65(2):100497.","journal-title":"J Lipid Res"},{"issue":"4","key":"5931_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4093\/dmj.2022.0198","volume":"46","author":"K Kim","year":"2022","unstructured":"Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J. 2022;46(4):517\u201332.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"5931_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/gutjnl-2023-330784","volume":"73","author":"L Chen","year":"2024","unstructured":"Chen L, Qiu W, Sun X, et al. Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis. Gut. 2024;73(3):521\u201332.","journal-title":"Gut"},{"issue":"1","key":"5931_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12872-024-04321-z","volume":"24","author":"S Zhang","year":"2024","unstructured":"Zhang S, Sun L, Xu X, et al. Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2024;24(1):629.","journal-title":"BMC Cardiovasc Disord"},{"key":"5931_CR18","doi-asserted-by":"publisher","first-page":"105841","DOI":"10.1016\/j.msard.2024.105841","volume":"91","author":"TR Wicks","year":"2024","unstructured":"Wicks TR, Nehzat N. Dyslipidemias in multiple sclerosis. Mult Scler Relat Disord. 2024;91:105841.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"5931_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-023-01633-x","volume":"24","author":"Y Bi","year":"2023","unstructured":"Bi Y, Zhu Y, Tang S, et al. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study. J Headache Pain. 2023;24(1):112.","journal-title":"J Headache Pain"},{"key":"5931_CR20","doi-asserted-by":"publisher","first-page":"1160312","DOI":"10.3389\/fimmu.2023.1160312","volume":"14","author":"H Tao","year":"2023","unstructured":"Tao H, Yu Z, Dong Y, et al. Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study. Front Immunol. 2023;14:1160312.","journal-title":"Front Immunol"},{"issue":"18","key":"5931_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"5931_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"8","key":"5931_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"5931_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"5931_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"12","key":"5931_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287\u201395.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"5931_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/01.ATV.19.2.321","volume":"19","author":"AM Brown","year":"1999","unstructured":"Brown AM, Wiggins D, Gibbons GF. Glucose phosphorylation is essential for the turnover of neutral lipid and the second stage assembly of triacylglycerol-rich ApoB-containing lipoproteins in primary hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1999;19(2):321\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"5931_CR28","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1093\/eurheartj\/ehaf207","volume":"46","author":"J Morze","year":"2025","unstructured":"Morze J, Melloni GEM, Wittenbecher C, et al. ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. 2025;46(27):2691\u2013701.","journal-title":"Eur Heart J"},{"issue":"9753","key":"5931_CR29","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"1","key":"5931_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12944-024-02307-6","volume":"23","author":"MB Rehman","year":"2024","unstructured":"Rehman MB, Tudrej BV. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk. Lipids Health Dis. 2024;23(1):316.","journal-title":"Lipids Health Dis"},{"key":"5931_CR31","doi-asserted-by":"crossref","unstructured":"Giannakopoulou SP, Antonopoulou S, Barkas F, et al. Concordance-discordance between apolipoprotein B and lipid biomarkers in predicting 20-year atherosclerotic cardiovascular disease risk: the ATTICA study (2002\u20132022). Eur J Clin Invest. 2025;55(10):e70077.","DOI":"10.1111\/eci.70077"},{"issue":"27","key":"5931_CR32","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","volume":"45","author":"AD Sniderman","year":"2024","unstructured":"Sniderman AD, Dufresne L, Pencina KM, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410\u20138.","journal-title":"Eur Heart J"},{"key":"5931_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pcad.2025.05.008","volume":"92","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Dis. 2025;92:108\u201317.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"5931_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1186\/s12967-025-07432-z","volume":"23","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al. Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. J Transl Med. 2025;23(1):1371.","journal-title":"J Transl Med"},{"issue":"6","key":"5931_CR35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/dom.13235","volume":"20","author":"YX Cao","year":"2018","unstructured":"Cao YX, Liu HH, Dong QT, et al. Effect of proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(6):1391\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"5931_CR36","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2174\/1381612823666170125154257","volume":"23","author":"VG Athyros","year":"2017","unstructured":"Athyros VG, Tziomalos K, Doumas M, et al. The effect of proprotein convertase subtilisin-kexin type 9 and its inhibition on glucose metabolism and cardiovascular risk. We should do better the second time after statins. Curr Pharm Des. 2017;23(10):1477\u201383.","journal-title":"Curr Pharm Des"},{"key":"5931_CR37","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Mu\u00f1oz Estrella A, Sourlas A, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63.","DOI":"10.3390\/diseases6030063"},{"issue":"7","key":"5931_CR38","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/17460441.2024.2360415","volume":"19","author":"D Tsamoulis","year":"2024","unstructured":"Tsamoulis D, Rallidis LS, Kosmas CE. Inclisiran: the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis. Expert Opin Drug Discov. 2024;19(7):773\u201382.","journal-title":"Expert Opin Drug Discov"},{"key":"5931_CR39","doi-asserted-by":"publisher","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","volume":"150","author":"C Macchi","year":"2019","unstructured":"Macchi C, Sirtori CR, Corsini A, et al. A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacol Res. 2019;150:104413.","journal-title":"Pharmacol Res"},{"issue":"21","key":"5931_CR40","doi-asserted-by":"publisher","first-page":"e026550","DOI":"10.1161\/JAHA.122.026550","volume":"12","author":"M Arca","year":"2023","unstructured":"Arca M, Celant S, Olimpieri PP, et al. Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: a retrospective cohort study based on the AIFA monitoring registries. J Am Heart Assoc. 2023;12(21):e026550.","journal-title":"J Am Heart Assoc"},{"key":"5931_CR41","first-page":"200261","volume":"21","author":"D Terentes-Printzios","year":"2024","unstructured":"Terentes-Printzios D, Dima I, Benardos P, et al. Real-world data on treatment patterns in at least high cardiovascular risk patients on dual and triple lipid lowering therapy in a Hellenic nationwide e-prescription database. Int J Cardiol Cardiovasc Risk Prev. 2024;21:200261.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"2","key":"5931_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"5931_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/0929867330666230228120601","volume":"31","author":"G Ghasempour","year":"2024","unstructured":"Ghasempour G, Zamani-Garmsiri F, Shaikhnia F, et al. Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Curr Med Chem. 2024;31(2):223\u201341.","journal-title":"Curr Med Chem"},{"issue":"9","key":"5931_CR44","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800\u20137.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"5931_CR45","doi-asserted-by":"publisher","first-page":"bvag001","DOI":"10.1210\/jendso\/bvag001","volume":"10","author":"F Di Giacomo Barbagallo","year":"2026","unstructured":"Di Giacomo Barbagallo F, Bosco G, Di Marco M, et al. Assessment of N\/L ratio and subclinical atherosclerosis in FH subjects with or without LDLR mutation. J Endocr Soc. 2026;10(3):bvag001.","journal-title":"J Endocr Soc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05931-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:03:02Z","timestamp":1783573382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5931"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05931-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of First Affiliated Hospital of Huzhou Universit. Written informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"583"}}